Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners?
Over the past two years, the US pharmaceutical and biotechnology industries were preparing themselves for passage of some type of health-reform legislation with a clear appreciation-and concern-about the enormous impact any law would be likely to have on the structure and viability of the research-based industry. Now, with final passage in March 2010 of the Patient Protection and Affordable Care Act and its companion "quick-fix" and budget bill, the Health Care and Education Reconciliation Act, it is a good time to take a look at how the industry fared and assess how the various provisions of the health-care reform bill might affect the industry's long-term prosperity and growth.
Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA. Christopher.milne@tufts.edu
C-P
CP
Milne
K I
KI
Kaitin
D002017:Budgets / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D017850:Economics, Pharmaceutical / Q000331:legislation & jurisprudence; D033161:Government Regulation; D017048:Health Care Costs / Q000331:legislation & jurisprudence; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D006801:Humans; D009937:Organizational Objectives; D014481:United States